CN1214246A - 抗菌组合药物 - Google Patents

抗菌组合药物 Download PDF

Info

Publication number
CN1214246A
CN1214246A CN 98113282 CN98113282A CN1214246A CN 1214246 A CN1214246 A CN 1214246A CN 98113282 CN98113282 CN 98113282 CN 98113282 A CN98113282 A CN 98113282A CN 1214246 A CN1214246 A CN 1214246A
Authority
CN
China
Prior art keywords
ceftazidime
sulbactam
beta
derivant
tazobactam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 98113282
Other languages
English (en)
Other versions
CN1096266C (zh
Inventor
吕华冲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiangbei Welman Pharmaceutical Co Ltd
Original Assignee
Wei'erman Pharmaceutic Co Ltd Guangzhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5223030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1214246(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wei'erman Pharmaceutic Co Ltd Guangzhou filed Critical Wei'erman Pharmaceutic Co Ltd Guangzhou
Priority to CN98113282A priority Critical patent/CN1096266C/zh
Publication of CN1214246A publication Critical patent/CN1214246A/zh
Application granted granted Critical
Publication of CN1096266C publication Critical patent/CN1096266C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种抗菌组合药物。它由头孢他啶与β－内酰胺酶抑制剂混合而成,头孢他啶与β－内酰胺酶的重量百分比为1∶2至10∶1(含端点)。头孢他啶为头孢他啶游离酸、头孢他啶五水合物、头孢他啶的碱金属盐以及头孢他啶游离酸的水合和非水合物加用碳酸钠或碳酸氢钠的形式,β－内酰胺酶抑制剂为棒酸及其衍生物,舒巴坦及其衍生物以及他佐巴坦及其衍生物。该产品不仅对敏感菌,而且对产酶菌有较好作用,其抗菌谱更广、抗菌作用更强。

Description

抗菌组合药物
本发明涉及一种头孢他啶(Ceftazidime)与β-内酰胺酶抑制剂组成的抗菌组合药物。
头孢他啶的抗菌谱广，抗菌作用强，对绿脓杆菌具有高度活性，其对金葡菌、A组溶血性链球菌、无乳链球菌、肺炎球菌、大肠杆菌、肺炎杆菌、奇异变形杆菌、普通变形杆菌、流感杆菌、百日咳杆菌、淋球菌与脑膜炎球菌等均有效。
到目前为止，头孢他啶通常仅以单一药物形式使用。然而，近来临床上发现，许多革兰氏阳性菌和阴性菌对头孢他啶形成耐药，许多重要病原菌中产生β-内酰胺酶的菌株明显增加，已引起人们关注。在大多数情况下，细菌耐药是由于其所产的β-内酰胺酶对抗生素的水解作用所致。因而使用头孢他啶时，加用一种能有效地抑制β-内酰胺酶作用的β-内酰胺酶抑制剂，更有利于头孢他啶稳定地发挥其抗菌作用，尤其对产β-内酰胺酶的病原体而言更是如此。因此，头孢他啶与β-内酰胺酶抑制剂组成的组合药物不仅对敏感菌，而且对产酶菌均有较好作用，其抗菌谱更广、抗菌作用更强。
本发明的目的在于提供一种抗菌谱更广、抗菌作用更强的头孢他啶与β-内酰胺酶抑制剂组成的抗菌组合药物。
本发明是这样实现的，它由头孢他啶和β-内酰胺酶抑制剂混合而成，头孢他啶与β-内酰胺酶抑制剂的重量比为1∶2至10∶1(含端点)。其中头孢他啶可以为头孢他啶游离酸、头孢他啶五水合物、头孢他啶的碱金属盐以及头孢他啶游离酸的水合和非水合物加用碳酸钠或碳酸氢钠的形式。β-内酰胺酶抑制剂为棒酸(Clavulanicacid)及其衍生物，舒巴坦(Sulbactam)及其衍生物以及他佐巴坦(Tazobactam)及其衍生物。而棒酸衍生物有棒酸的碱金属盐例如棒酸钾，舒巴坦有舒巴坦的碱金属盐例如舒巴坦钠；他佐巴坦衍生物有他佐巴坦的碱金属盐例如他佐巴坦钠。
本发明的粉针剂或冻干粉针剂可用于治疗细菌感染例如呼吸道感染、肝胆系统感染、腹腔内感染、盆腔感染和其他妇科感染、败血症、脑膜炎、皮肤软组织感染、骨髓炎。本发明的粉针剂或冻干粉针剂通常适用于治疗对β-内酰胺类抗生素敏感的微生物感染，也对一些耐青霉素微生物有效。
下面结合实施例对本发明作进一步详述。
实施例1：头孢他啶组合药物由头孢他啶1克与棒酸钾0.5克制成组合制剂，按粉针剂制备工艺程序操作进行。
实施例2：头孢他啶组合药物由头孢他啶1克与棒酸钾0.5克制成组合制剂，按冻干粉针制剂工艺程序进行。
实施例3：头孢他啶组合药物由头孢他啶1克与棒酸钾0.25克制成组合制剂，按粉针剂制备工艺程序操作进行。
实施例4：头孢他啶组合药物由头孢他啶1克与棒酸钾0.25克制成组合制剂，按冻干粉针剂制备工艺程序操作。
实施例5：头孢他啶组合药物由头孢他啶1克与舒巴坦钠1克制成组合制剂，按粉针剂制备工艺程序操作。
实施例6：头孢他啶组合药物由头孢他啶1克与舒巴坦钠1克制成组合制剂，按冻干粉针剂制备工艺程序操作。
实施例7，头孢他啶组合药物由头孢他啶0.5克与舒巴坦钠1克制成组合制剂，按粉针剂制备工艺程序操作。
实施例8，头孢他啶组合药物由头孢他啶1克与舒巴坦钠0.5克制成组合制剂，按冻干粉针剂制备工艺程序进行。
实施例9，头孢他啶组合药物由头孢他啶1克与他佐巴坦钠0.25克制成组合制剂，按粉针剂制备程序进行。
实施例10，头孢他啶组合药物由头孢他啶1克与他佐巴坦钠0.125克制成组合制剂，按冻干粉针剂制备工艺程序操作。
实施例11，头孢他啶组合药物由头孢他啶1克与他佐巴坦钠0.125克制成组合制剂，按粉针剂制备工艺程序进行。
实施例12，头孢他啶组合药物由头孢他啶1克与他佐巴坦钠0.125克制成组合制剂，按冻干粉针剂制备工艺程序进行。
本发明不限于以上所述的实施例。
本发明的组合制剂经体外试验证明，其抗菌活性及抗菌谱比头孢他啶应用时作用更强。
表1头孢他啶与头孢他啶/棒酸的抗菌作用(MIC mg/L)
     细菌  株数 头孢他啶 头孢他啶/棒酸(1∶4)
大肠杆菌     14     32     0.25
阴沟肠杆菌     22     128     16
克雷伯氏肺炎杆菌     10     8     0.125
绿脓杆菌     6     25.6     16
粘氏沙雷氏菌     14     4     0.125
金黄色葡萄球菌     18     16     0.5
表皮葡萄球菌     4     128     16
溶血链球菌     26     32     0.25
表2头孢他啶与头孢他啶舒巴坦的抗菌作用(MIC mg/L)
    细菌  株数 头孢他啶 头孢他啶/棒酸(1∶1)
金黄色葡萄球菌   14     16     1
溶血链球菌   20     64     4
肺炎球菌   10     2     0.125
大肠杆菌   18     16     0.125
粘氏沙雷菌   12     4     0.25
绿脓杆菌   8     256     32
克雷伯氏肺炎杆菌   8     16     0.5
氟氏拘橼酸杆菌   20     128     32
奇异变形杆菌   16     8     0.125
表3 头孢他啶与头孢他啶/他佐巴坦的抗菌作用(MIC mg/L)
    细菌    株数 头孢他啶 头孢他啶/他佐马坦(4∶1)
大肠杆菌     16     16     2
阴沟肠杆菌     18     128     8
氟氏枸橼酸杆菌     16     128     16
绿脓杆菌     10     256     8
金黄色葡萄球菌     14     32     2
溶血性链球菌     20     32     0.5
粘氏沙雷氏菌     24     4     0.125
本发明的粉针剂或冻干粉针剂通常适用于治疗对β-内酰胺酶敏感的微生物感染，也对一些耐青霉素微生物有效，可用于治疗细菌感染例如呼吸道感染，肝胆系统感染，腹腔内感染，盆腔感染和其他妇科感染、败血症、脑膜炎，皮肤软组织感染和骨髓炎。并适用于由上述常见病原体引起的动物的感染，因而也可用于兽类感染疾病的治疗。
本发明药物的单位剂量通常为注射给药，可作静脉推注，快速静脉滴入或肌肉注射。头孢他啶每日适当的总剂量为1500-6000毫克，每日三次给药。
综上所述，按照本发明的药物，β-内酰胺酶抑制剂与头孢他啶间具有显著的协同作用，能明显地增强头孢他啶的抗菌活性和抗菌谱。从而有效地解决细菌越来越多的对头孢他啶耐药问题，增强药物的临床疗效。

Claims (3)

1．一种抗菌组合药物，其特征在于：它由头孢他啶与β-内脱胺酶抑制剂混合而成，头孢他啶与β-内酰胺酶抑制剂的重量百分比为1∶2至10∶1(含端点)。
2．根据权利要求1所述的抗菌组合药物，其特征在于：头孢他啶为头孢他啶游离酸、头孢他啶五水合物、头孢他啶的碱金属盐以及头孢他啶游离酸的水合和非水合物加用碳酸钠或碳酸氢钠的形式。
3．根据权利要求1所述的抗菌组合药物，其特征在于：β-内酰胺酶抑制剂为棒酸(Clavulanic acid)及其衍生物，舒巴坦(Sulbactam)及其衍生物以及他佐巴坦(Tazobactam)及其衍生物；而棒酸衍生物有棒酸的碱金属盐例如棒酸钾，舒巴坦衍生物有舒巴坦的碱金属盐例如舒巴坦钠；他佐巴坦衍生物有他佐巴坦的碱金属盐例如他佐巴坦钠。
CN98113282A 1998-07-15 1998-07-15 抗菌组合药物 Ceased CN1096266C (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN98113282A CN1096266C (zh) 1998-07-15 1998-07-15 抗菌组合药物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN98113282A CN1096266C (zh) 1998-07-15 1998-07-15 抗菌组合药物

Publications (2)

Publication Number Publication Date
CN1214246A true CN1214246A (zh) 1999-04-21
CN1096266C CN1096266C (zh) 2002-12-18

Family

ID=5223030

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98113282A Ceased CN1096266C (zh) 1998-07-15 1998-07-15 抗菌组合药物

Country Status (1)

Country Link
CN (1) CN1096266C (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1321183C (zh) * 2004-11-25 2007-06-13 上海医药工业研究院 具有抑制β－内酰胺酶抑制活性的多肽及编码的DNA
CN101849949A (zh) * 2010-06-17 2010-10-06 深圳市新泰医药有限公司 一种头孢匹林钠和舒巴坦钠的组合物及其配比
CN104147013A (zh) * 2013-09-09 2014-11-19 海南康芝药业股份有限公司 一种抗耐药菌组合物及其制法
WO2020177546A1 (zh) * 2019-03-05 2020-09-10 广州新创忆药物临床研究有限公司 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100384857C (zh) * 2003-11-28 2008-04-30 浙江永宁制药厂 耐β-内酰胺酶的头孢菌素酯化合物及其盐

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1321183C (zh) * 2004-11-25 2007-06-13 上海医药工业研究院 具有抑制β－内酰胺酶抑制活性的多肽及编码的DNA
CN101849949A (zh) * 2010-06-17 2010-10-06 深圳市新泰医药有限公司 一种头孢匹林钠和舒巴坦钠的组合物及其配比
CN101849949B (zh) * 2010-06-17 2012-05-23 深圳市新泰医药有限公司 一种头孢匹林钠和舒巴坦钠的组合物及其配比
CN104147013A (zh) * 2013-09-09 2014-11-19 海南康芝药业股份有限公司 一种抗耐药菌组合物及其制法
WO2020177546A1 (zh) * 2019-03-05 2020-09-10 广州新创忆药物临床研究有限公司 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物
CN113382734A (zh) * 2019-03-05 2021-09-10 广州新创忆药物临床研究有限公司 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物

Also Published As

Publication number Publication date
CN1096266C (zh) 2002-12-18

Similar Documents

Publication Publication Date Title
Hathorn et al. Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches
Smith et al. Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus
CN1074931C (zh) 抗葡萄球菌的抗微生物剂及其用途
CN1096266C (zh) 抗菌组合药物
Gadebusch et al. Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents
Chin et al. Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection
US5610139A (en) Antimicrobial compositions and pharmaceutical preparations thereof
Mayer et al. Bacterial pathogens of increasing significance in hospital-acquired infections
Haase et al. Comparative in vitro activity of norfloxacin against urinary tract pathogens
Farca et al. Potentiation of antibiotic activity by EDTA-tromethamine against three clinically isolated gram-positive resistant bacteria. An in vitro investigation
US20060073156A1 (en) Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract
Johnson et al. Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis
Sanders et al. Current antimicrobial therapy of anaerobic infections
CN1059086C (zh) 抗β-内酰胺酶抗菌素复合物
Nagy et al. In vitro activity of daptomycin-metronidazole combinations against mixed bacterial cultures: reduced activity of metronidazole against Bacteroides species in the presence of Enterococcus faecalis
CN1709263A (zh) 抗菌素组合物
CN1183959A (zh) 抑制β－内酰胺酶的抗菌素组合物
Giamarellou et al. In-vitro studies with ceftazidime
CN1706388A (zh) 一种新的抗菌药物组合物
CN1823738A (zh) 注射用粉针剂及其制备方法
Odenholt et al. Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase
Norrby Future trends in antibiotic therapy
CN1582941A (zh) 抗菌药物组合物
Edlund et al. Suppression of the oropharyngeal and gastrointestinal microflora by ciprofloxacin: microbiological and clinical consequences
Fu et al. Activity of 5-episisomicin compared with that of other aminoglycosides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SUN MINGJIE

Free format text: FORMER OWNER: WEI'ERMAN PHARMACEUTIC CO. LTD., GUANGZHOU

Effective date: 20030627

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20030627

Address after: Guangdong Province, Guangzhou City Road No. 11 days Run Guangdong building 33A

Patentee after: Sun Mingjie

Address before: Guangzhou City, Guangdong province 57-5 richlink Shuiyinlu Plaza Jiaxing building A201

Patentee before: Guangzhou Viaman Pharmaceutical Co.,Ltd.

PP01 Preservation of patent right

Effective date of registration: 20060413

Pledge (preservation): Preservation

PD01 Discharge of preservation of patent

Date of registration: 20061013

Pledge (preservation): Preservation

PP01 Preservation of patent right

Effective date of registration: 20061013

Pledge (preservation): Preservation

PD01 Discharge of preservation of patent

Date of cancellation: 20081013

Pledge (preservation): Preservation registration

PP01 Preservation of patent right

Effective date of registration: 20090415

Pledge (preservation): Preservation

PD01 Discharge of preservation of patent

Date of cancellation: 20091015

Pledge (preservation): Preservation registration

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20100108

Address after: 33A 11, Tianhe building, Tianhe Road, Guangdong, Guangzhou, China: 510075

Co-patentee after: Xiangbei Welman Pharmaceutical Co., Ltd.

Patentee after: Sun Ming Jie

Address before: 33A 11, Tianhe building, Tianhe Road, Guangdong, Guangzhou, China: 510075

Patentee before: Sun Mingjie

ASS Succession or assignment of patent right

Free format text: FORMER OWNER: XIANGBEI WELMAN PHARMACEUTICAL CO., LTD.

Owner name: XIANGBEI WELMAN PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: SUN MINGJIE

Effective date: 20100519

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 510075 33A, RUNYUE BUILDING, NO.11 TIANHE ROAD, GUANGZHOU CITY, GUANGDONG PROVINCE TO: 410331 DONGJING TOWNSHIP (BIOMEDICAL PARK), LIUYANG CITY, HUNAN PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20100519

Address after: 410331, Liuyang City, Hunan Province Hole township (Biological Medicine Park)

Patentee after: Xiangbei Welman Pharmaceutical Co., Ltd.

Address before: 510075, Guangdong Province, Tianhe Road, Guangdong, Guangdong Province building 33A 11 Guangzhou

Co-patentee before: Xiangbei Welman Pharmaceutical Co., Ltd.

Patentee before: Sun Mingjie

C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: 410331, Liuyang City, Hunan Province Hole township (Biological Medicine Park)

Patentee after: Xiangbei Welman Pharmaceutical Co., Ltd.

Address before: 410331, Liuyang City, Hunan Province Hole township (Biological Medicine Park)

Patentee before: Xiangbei Welman Pharmaceutical Co., Ltd.

EE01 Entry into force of recordation of patent licensing contract

Application publication date: 19990421

Assignee: Hainan Honz Pharmaceutical Co., Ltd.

Assignor: Xiangbei Welman Pharmaceutical Co., Ltd.

Contract record no.: 2013460000002

Denomination of invention: Natural antibiotic composition extracted from lily and its extraction process

Granted publication date: 20021218

License type: Common License

Record date: 20130129

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 19990421

Assignee: Guoruitang Pharmaceutical Co., Ltd., Hainan Prov.

Assignor: Xiangbei Welman Pharmaceutical Co., Ltd.

Contract record no.: 2011990000404

Denomination of invention: Combined antibiotic medicine for inhibiting beta-lactamase

Granted publication date: 20021218

License type: Common License

Record date: 20110527

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
PP01 Preservation of patent right

Effective date of registration: 20150506

Granted publication date: 20021218

RINS Preservation of patent right or utility model and its discharge
PD01 Discharge of preservation of patent

Date of cancellation: 20160127

Granted publication date: 20021218

RINS Preservation of patent right or utility model and its discharge
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20021218

IW01 Full invalidation of patent right
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20160706

Decision number of declaring invalidation: 29543

Granted publication date: 20021218